Increasing chemotherapy dose intensity reduced the risk of recurrence and death over standard chemotherapy regimens, according to a meta-analysis of women with early-stage breast cancer.
Adding trastuzumab to adjuvant chemotherapy did not result in improved rates of invasive disease-free survival in patients with early-stage breast cancer and low levels of HER2 expression, according to a new study.
Traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade yielded significantly better response rates than a novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade, according to a randomized phase III trial.
A novel classification system that incorporates genomic risk with clinical variables was able to accurately identify prostate cancer patients at low, intermediate, and high risk for metastasis.
An intermittent schedule with extended adjuvant letrozole did not improve disease-free survival in postmenopausal breast cancer patients.
A 5-year follow-up analysis showed that 1 year of extended adjuvant therapy with neratinib, given after chemotherapy and trastuzumab, can significantly improve rates of clinically relevant relapses in women with HER2-positive breast cancer.
The LMWH enoxaparin failed to improve overall or progression-free survival in small-cell lung cancer patients, in spite of improved rates of venous thromboembolism.
Duloxetine resulted in reduced AI-associated musculoskeletal symptoms compared with placebo in women with early-stage breast cancer.
The addition of bevacizumab to adjuvant chemotherapy failed to improve survival outcomes in patients with surgically resected early-stage NSCLC.
The FDA has granted approval for the use of dasatinib (Sprycel) in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.